As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.

On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work

outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.

The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.

Hainan Haiyao Co., Ltd.

Hainan Haiyao Co., Ltd.

Company Overview


Haiyao is primarily engaged in manufacturing pharmaceuticals and medical devices. Its portfolio includes influenza antiviral drugs, antibiotic intermediates, and cochlear implants. The company has several facilities and subsidiaries in the United States that focus on R&D and sales.


Liu Xicheng


Haikou, Hainan


(898) 6865.3568